Utilizing Diagnostics to Inform Patient Stratification and Selection in Clinical Trials

Time: 11:30 am
day: Day One


  • Molecular imaging with PET/CT provides immense value for both patient selection and as a prognostic/predictive biomarker
  • For PSMA theranostics, the value of FDG in addition to PSMA PET/CT will be highlighted
  • It is particularly critical for phase I/II to enrich patients likely to benefit from therapy